Screener
Zevra Therapeutics, Inc. ZVRA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | (4,042) | (2,199) | (10,957) | (3,381) |
| Net income | $8,752 | $74,707 | $46,642 | $71,608 |
| Net income per share of common stock: | ||||
| Basic | $0.14 | $1.24 | $0.76 | $1.20 |
| Diluted | $0.14 | $1.21 | $0.74 | $1.16 |
| Weighted-average shares of common stock outstanding: | ||||
| Basic | 59,155,970 | 54,780,938 | 58,783,034 | 54,440,100 |
| Diluted | 61,336,617 | 56,324,903 | 60,785,625 | 56,062,443 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s EPS (diluted)?
- Zevra Therapeutics, Inc. (ZVRA) reported EPS (diluted) of $0.14 in Q2 2026.
- How has Zevra Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Zevra Therapeutics, Inc.'s EPS (diluted) decreased by 88.4% year-over-year, from $1.21 to $0.14.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Zevra Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude